Yichun Qian's questions to Karyopharm Therapeutics Inc (KPTI) leadership • Q1 2025
Question
Yichun Qian, on behalf of Maury Raycroft, asked about the company's confidence in completing myelofibrosis trial enrollment by July, plans for a press release, baseline characteristics of enrolled patients, and patient compliance with daily TSS measurements.
Answer
Richard Paulson, President and CEO, confirmed the company is 80% enrolled and will issue a press release upon reaching its target. Reshma Rangwala, EVP and Chief Medical Officer, added that baseline characteristics are similar to the Phase I trial but with higher baseline TSS scores due to inclusion criteria. She also affirmed that patient compliance with daily electronic TSS reporting is very high due to diligent monitoring.